Effects of Celecoxib After Percutaneous Coronary Intervention

Phase 4

Completed

• Conditions: Coronary Arteriosclerosis
• Interventions: Drug: Celecoxib

• Registration Number: NCT00292721
• Lead Sponsor: Seoul National University Hospital

Brief Summary

Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-08
• Study First Submitted: 2006-02-15
• Study First Submitted QC: 2006-02-15
• Study First Posted: 2006-02-16
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Status Verified: 2011-07
• Last Update Submitted: 2011-07-20
• Last Update Posted: 2011-07-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 260

Inclusion Criteria

• Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography

Exclusion Criteria

• Acute ST elevation MI
• Left main disease
• Contraindications to aspirin, clopidogrel or celecoxib
• Severe congestive heart failure
• Expected survival < 2 years
• Hepatic dysfunction
• Currently taking NSAIDs or any COX-2 inhibitor
• Renal dysfunction
• Use of warfarin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Celecoxib	Celecoxib	-

Primary Outcome Measures

Name	Time	Method
Late luminal loss at 6 months	6 months

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of